drugset / Trial / NCT06001606

Immunogenicity, Reactogenicity of Shingrix in SLE

NCT06001606

Phase 3 Unknown 63 enrolled Seoul National University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the immunogenicity, reactogenicity and safety of 2 doses of the adjuvanted herpes zoster subunit vaccine (Shingrix) in patients with SLE in a randomized trial.

Timeline

Start
2023-05-08
Primary completion
2025-04-24
Completion
2025-04-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine